Download Sample, Increasing Prevalence of Psychiatric Disorders and Innovation in Therapies Led to Market Growth
Increasing incidences of mental disorders such as schizophrenia, bipolar disorder, and other psychotic disorders significantly fuel the demand for antipsychotic medications. Growing diagnoses and the need for efficient treatment spur market growth; in this case, such significant mental conditions demand advanced antipsychotic drugs to be utilized. For instance, severe factors are triggering such prevalence, as per the World Health Organisation, the global burden of mental health conditions over 1 billion people are living with mental, neurological, and substance use disorders. In addition, about 46 million people around the world, including 2.8% of the total U.S. population, have bipolar disorder. Additionally, schizophrenia impacts around 24 million individuals, or 1 in every 300 people (0.32%) globally. This ratio is 1 in 222 individuals (0.45%) among adults.
Nevertheless, it is not as frequent as other mental disorders. The onset typically occurs during late adolescence and the twenties, with men usually experiencing it earlier than women. Schizophrenia is often linked to considerable distress and dysfunction in personal, familial, social, educational, occupational, and various crucial aspects of life. For instance, a study from Finland revealed that the lifetime prevalence of psychotic disorders is 3.06%. Additional research has discovered comparable findings, with lifetime prevalence levels between 2.47% and 3.48%. Such increased prevalence of mental disorders will propel market growth for antipsychotic drugs with growing awareness about timely intervention and diagnosis.
Furthermore, new medications for mental health issues are vital as they provide potentially more effective and targeted therapies with enhanced side effect profiles, enabling better symptom control and possibly quicker relief than traditional drugs, especially for individuals with treatment-resistant conditions, while also paving the way for innovative mechanisms of action that could tackle previously challenging aspects of mental disorders; however, continuous research and vigilant monitoring are essential to comprehensively assess their efficacy and safety.
For instance, in September 2024, the U.S. Food and Drug Administration authorized Cobenfy (xanomeline and trospium chloride) capsules for oral administration to treat schizophrenia in adult patients. It is the initial antipsychotic medication authorized for treating schizophrenia that focuses on cholinergic receptors rather than dopamine receptors, which have traditionally been the standard treatment. Such product innovations with enhanced profiles will lead to more market adoption.
Nevertheless, it is not as frequent as other mental disorders. The onset typically occurs during late adolescence and the twenties, with men usually experiencing it earlier than women. Schizophrenia is often linked to considerable distress and dysfunction in personal, familial, social, educational, occupational, and various crucial aspects of life. For instance, a study from Finland revealed that the lifetime prevalence of psychotic disorders is 3.06%. Additional research has discovered comparable findings, with lifetime prevalence levels between 2.47% and 3.48%. Such increased prevalence of mental disorders will propel market growth for antipsychotic drugs with growing awareness about timely intervention and diagnosis.
Furthermore, new medications for mental health issues are vital as they provide potentially more effective and targeted therapies with enhanced side effect profiles, enabling better symptom control and possibly quicker relief than traditional drugs, especially for individuals with treatment-resistant conditions, while also paving the way for innovative mechanisms of action that could tackle previously challenging aspects of mental disorders; however, continuous research and vigilant monitoring are essential to comprehensively assess their efficacy and safety.
For instance, in September 2024, the U.S. Food and Drug Administration authorized Cobenfy (xanomeline and trospium chloride) capsules for oral administration to treat schizophrenia in adult patients. It is the initial antipsychotic medication authorized for treating schizophrenia that focuses on cholinergic receptors rather than dopamine receptors, which have traditionally been the standard treatment. Such product innovations with enhanced profiles will lead to more market adoption.
Expanding Market in Emerging Economies with Improved Drugs Class Further Drive Market Adoption
A developing nation is marked by prevalent chronic poverty and exhibits low economic progress in comparison to other countries. There are 47 nations identified as developing countries, with South Sudan and Chad scoring below 0.4 on the Human Development Index. However, developed nations experience a greater prevalence of mental health problems than less affluent countries. For instance, Australia and New Zealand, classified as high-income nations, exhibited the highest lifetime prevalence rates of anxiety 8% and 7.9%, respectively. Nigeria (0.1%) and Shenzhen, China (0.2%) reported the lowest rates; both were classified as low-income regions which further reflects the need for antipsychotic drugs in developed and developing countries.
Additionally, the health spending per person in countries differs based on their level of economic development. While high-income nations allocate an average of US$3,000 per citizen for healthcare, low-income nations spend merely up to US$30 per person. With the growing healthcare infrastructure and facilities in developing nations with increased mental health awareness, there is an opportunity for anti-psychotic drugs market penetration in such regions.
Moreover, new drug classes with regulatory approval will boost market growth during the forecast period. For instance, in September 2024, KarXT, the first medication featuring a novel mechanism of action, received US regulatory approval. The endorsement brings the promise of an antipsychotic that could be more effective and easier to tolerate than existing treatments. Apart from this, extended-release medications, often referred to by doctors or healthcare professionals as long-acting injectables, alleviate symptoms in the same manner as daily tablets. These medications are referred to as antipsychotics. They alter the behavior of certain chemicals in the human brain. While adoption of such injectables in routine treatment in such cases will propel market development in the near future.
Additionally, the health spending per person in countries differs based on their level of economic development. While high-income nations allocate an average of US$3,000 per citizen for healthcare, low-income nations spend merely up to US$30 per person. With the growing healthcare infrastructure and facilities in developing nations with increased mental health awareness, there is an opportunity for anti-psychotic drugs market penetration in such regions.
Moreover, new drug classes with regulatory approval will boost market growth during the forecast period. For instance, in September 2024, KarXT, the first medication featuring a novel mechanism of action, received US regulatory approval. The endorsement brings the promise of an antipsychotic that could be more effective and easier to tolerate than existing treatments. Apart from this, extended-release medications, often referred to by doctors or healthcare professionals as long-acting injectables, alleviate symptoms in the same manner as daily tablets. These medications are referred to as antipsychotics. They alter the behavior of certain chemicals in the human brain. While adoption of such injectables in routine treatment in such cases will propel market development in the near future.
Recent Trends in Antipsychotic Drugs Market
- Increasing prevalence of mental disorders such as bipolar and schizophrenia
- Increased awareness and focus on mental health, timely intervention, and diagnosis
- Drug innovation with enhanced safety profiles over traditional drug class
- Regulatory approvals by the USFDA to ensure safety and effectiveness
- Increased R&D investment by governments and multiple clinical trials
Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs…!
Possible Side Effects and Product Recalls Over Safety Issues Will Potentially Hamper Market Growth
With the rise in prevalence, there is a need for more improved drug classes for such mental disorders. As it gives notable effects in treatment, its possible side effects in long-term use pose a significant threat to market adoption. For instance, with treatment including first and second-generation antipsychotic drugs, patients may suffer from side effects such as abnormal movements, dizziness and sedation, drug-induced movement disorders, heart and circulatory problems, high blood sugar, high cholesterol, high prolactin levels, tardive dyskinesia and other effects with all antipsychotic drug class. However, randomized clinical trials are necessary to ensure drug profile with effectiveness and reduced effects. Failure to ensure drug efficiency leads to lower product sales and patient negative perception of specific drugs.
Furthermore, product recalls in the healthcare and pharmaceutical industry are one of the major threats to the market as a well-established key player owing to health concerns and their reputation as well as their position in the market. For instance, the FDA declared a Class II recall on over 7,000 bottles of an antidepressant after discovering a toxic substance in October 2024. Conversely, Duloxetine is a medication utilized for addressing mental health issues like anxiety and depression, in addition to other ailments. However, product recalls pose a threat to the patient’s health and reputation damage to the key players. Additionally, in November 2024, the medication for anxiety Clonazepam was recalled due to a label error that is dangerous to life, as per the Food and Drug Administration (FDA).
As per federal agencies' confirmation, Endo Inc. has issued a voluntary recall for 16 lots of clonazepam orally disintegrating tablets. The immediate recall for 16 lots of the anti-anxiety drug due to mislabelling with the wrong strength and National Drug Code or NDC. The Otsuka America Pharmaceutical, Inc. (Otsuka) recently issued a voluntary recall in April 2024 for certain Abilify or more appropriately called aripiprazole tablets within the United States, owing to possible cross-contamination from small amounts of another active pharmaceutical ingredient prepared on the same equipment. Abilify (ariprazole) tablets at the strength of 5 mg, 10 mg, 15 mg, and 30 mg were impacted. Such product recalls and the potential side effects associated with the drug will lead to hampering market growth globally.
Furthermore, product recalls in the healthcare and pharmaceutical industry are one of the major threats to the market as a well-established key player owing to health concerns and their reputation as well as their position in the market. For instance, the FDA declared a Class II recall on over 7,000 bottles of an antidepressant after discovering a toxic substance in October 2024. Conversely, Duloxetine is a medication utilized for addressing mental health issues like anxiety and depression, in addition to other ailments. However, product recalls pose a threat to the patient’s health and reputation damage to the key players. Additionally, in November 2024, the medication for anxiety Clonazepam was recalled due to a label error that is dangerous to life, as per the Food and Drug Administration (FDA).
As per federal agencies' confirmation, Endo Inc. has issued a voluntary recall for 16 lots of clonazepam orally disintegrating tablets. The immediate recall for 16 lots of the anti-anxiety drug due to mislabelling with the wrong strength and National Drug Code or NDC. The Otsuka America Pharmaceutical, Inc. (Otsuka) recently issued a voluntary recall in April 2024 for certain Abilify or more appropriately called aripiprazole tablets within the United States, owing to possible cross-contamination from small amounts of another active pharmaceutical ingredient prepared on the same equipment. Abilify (ariprazole) tablets at the strength of 5 mg, 10 mg, 15 mg, and 30 mg were impacted. Such product recalls and the potential side effects associated with the drug will lead to hampering market growth globally.
Product Launches by Key Players will Boost Market Demand
Continuous product innovation in drug classes for mental disorders such as schizophrenia and bipolar disorders and clinical trials over the rising safety issue to ensure its safety and efficacy by key players and regulatory bodies plays a significant role in market adoption globally. For instance, in September 2024, in a significant development for individuals with schizophrenia, the FDA authorized a new oral treatment for adults. In contrast to conventional antipsychotic medications, the drug, to be sold as Cobenfy, focuses on an alternative brain pathway, providing fresh optimism for therapy.
Additionally, in November 2024, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd announced encouraging findings on social functioning and quality of life from the phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial assessing TEV-'749 in adult individuals diagnosed with schizophrenia. During the initial treatment phase of the study (Period 1), TEV-'749 showed considerable enhancement in social functioning and quality of life through several validated measures from the baseline to week 8. The systemic safety profile of TEV-'749 aligned with that of other authorized oral formulations of olanzapine, with no new safety signals detected and no PDSS events reported so far. In addition, in June 2024, Intra-Cellular Therapies Announced Positive Topline results in the second phase 3 trial evaluating Lumateperone as adjunctive therapy in patients with major depressive disorder.
Additionally, in November 2024, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd announced encouraging findings on social functioning and quality of life from the phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial assessing TEV-'749 in adult individuals diagnosed with schizophrenia. During the initial treatment phase of the study (Period 1), TEV-'749 showed considerable enhancement in social functioning and quality of life through several validated measures from the baseline to week 8. The systemic safety profile of TEV-'749 aligned with that of other authorized oral formulations of olanzapine, with no new safety signals detected and no PDSS events reported so far. In addition, in June 2024, Intra-Cellular Therapies Announced Positive Topline results in the second phase 3 trial evaluating Lumateperone as adjunctive therapy in patients with major depressive disorder.
Searching for a Country or Region Specific Report?
Unlock industry complexities with reports crafted for selected countries and regions at Reduced Cost
North America Dominates the Antipsychotic Drugs Market
In North America, the growing prevalence of mental disorders, schizophrenia, and bipolar diseases primarily in the US will significantly drive the need for such drugs with timely intervention and focus on mental as well as overall health. For instance, bipolar disorder affects around 5.7 million adult Americans, which translates to about 2.6% of the U.S. population aged 18 and older annually according to the National Institute of Health (NIH). Also, the age of onset of bipolar disorder has been known to be around 25 years. It starts at a very young age and may start even from early childhood or may as well begin in the 40s and 50s. Bipolar disorder manifests in an equal number of men and women, affecting individuals regardless of age, race, ethnicity, or social status.
In addition, according to the Mental Health America report, 23.08% of adults faced a mental health issue in the previous year, which amounts to approximately 60 million Americans. 5.86% encountered a serious mental health condition. The prevalence of adult mental illness in states varies from 19.38% in New Jersey to 29.19% in Utah. Additionally, the United States considered a major hub for research and development (R&D) with the presence of prominent key players will further dominate North America for antipsychotic drugs.
Furthermore, Asia Pacific is the fastest growing region in the global antipsychotic drugs market because of the growing geriatric and other age group population suffering from a variety of mental illnesses which significantly drives demand for the new class of drugs with increased efficacy and fewer side effects. For instance, one prevalence shows that the lifetime prevalence of bipolar disorder in Asia is approximately estimated at 0.2% while the 12-month prevalence is approximately 0.1%. Similarly, according to one report, the prevalence of schizophrenia is said to occur in about 1.0% population in the world, while its lifetime prevalence in China ranges from 0.5-0.9%.
In addition, according to the Mental Health America report, 23.08% of adults faced a mental health issue in the previous year, which amounts to approximately 60 million Americans. 5.86% encountered a serious mental health condition. The prevalence of adult mental illness in states varies from 19.38% in New Jersey to 29.19% in Utah. Additionally, the United States considered a major hub for research and development (R&D) with the presence of prominent key players will further dominate North America for antipsychotic drugs.
Furthermore, Asia Pacific is the fastest growing region in the global antipsychotic drugs market because of the growing geriatric and other age group population suffering from a variety of mental illnesses which significantly drives demand for the new class of drugs with increased efficacy and fewer side effects. For instance, one prevalence shows that the lifetime prevalence of bipolar disorder in Asia is approximately estimated at 0.2% while the 12-month prevalence is approximately 0.1%. Similarly, according to one report, the prevalence of schizophrenia is said to occur in about 1.0% population in the world, while its lifetime prevalence in China ranges from 0.5-0.9%.
The report provides a detailed overview of the antipsychotic drugs market insights in regions including North America, Latin America, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. The country-specific assessment for the antipsychotic drugs market has been offered for all regional market shares, along with forecasts, market scope estimates, price point assessment, and impact analysis of prominent countries and regions. Throughout this market research report, Y-o-Y growth and CAGR estimates are also incorporated for every country and region, to provide a detailed view of the antipsychotic drugs market. These Y-o-Y projections on regional and country-level markets brighten the political, economic, and business environment outlook, which are anticipated to have a substantial impact on the growth of the antipsychotic drugs market. Some key countries and regions included in the antipsychotic drugs market report are as follows:
| North America | United States, Canada |
| Latin America | Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America |
| Europe | Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Norway, Denmark, Finland, Ireland, Czech Republic, Rest of Europe |
| Asia Pacific | China, India, Japan, South Korea, Australia & New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific |
| Middle East and Africa | GCC Countries, South Africa, Egypt, Turkey, Morocco, Israel, Iran, Kenya, Nigeria, Rest of MEA |
Antipsychotic Drugs Market Research Report Covers In-depth Analysis on:
- Antipsychotic drugs market detailed segments and segment-wise market breakdown
- Antipsychotic drugs market dynamics (Recent industry trends, drivers, restraints, growth potential, opportunities in the antipsychotic drugs industry)
- Current, historical, and forthcoming 10 years market valuation in terms of antipsychotic drugs market size (US$ Mn), volume (Tons), share (%), Y-o-Y growth rate, CAGR (%) analysis
- Antipsychotic drugs market demand analysis
- Antipsychotic drugs market pricing analysis over the forecast period (by key segment and by region)
- Antipsychotic drugs market regional insights with region-wise market breakdown
- Competitive analysis – key companies profiling including their market share, product offerings, and competitive strategies.
- Latest developments and innovations in the antipsychotic drugs market
- Regulatory landscape by key regions and key countries
- Supply chain and Value Chain Analysis in the antipsychotic drugs market
- Antipsychotic drugs market sales and distribution strategies
- A comprehensive overview of the parent market
- A detailed viewpoint on the antipsychotic drugs market forecast by countries
- Mergers and acquisitions in the antipsychotic drugs market
- Essential information to enhance market position
- Robust research methodology
- Frequently Asked Questions -
What are the key drivers of growth in the antipsychotic drugs market?
The antipsychotic drugs market growth is driven by increasing cases of psychiatric disorders, advancements in drug formulations, and rising awareness of mental health, alongside improved treatment options for patients.
What challenges are faced in the antipsychotic drugs market?
Key challenges include managing the side effects of antipsychotic drugs, the high cost of treatment, and regulatory hurdles for new drug approvals, all of which impact market expansion and patient access.
What are the emerging trends in the antipsychotic drugs market?
Trends include the development of long-acting injectable forms, personalized medicine, and the incorporation of digital health technologies to improve drug adherence and treatment monitoring.
